Hybrid Vigor Volume 1 Issue 3

Click here to download a PDF of the newsletter

Dear Friends,

Welcome to the second week and third beta edition of our institutional flagship product Hybrid Vigor, the Hillside Convertible Advisory Letter. We're thrilled with the reception and feedback we've received thus far.  We hope Hybrid Vigor will become a standard part of your market review and idea generation processes. Please keep your feedback coming.

As a reminder, we plan to publish beta editions of Hybrid Vigor through mid-fall, at which point we will be going to a subscription-based model.

In today's edition we introduce a list of bonds that score favorably on our proprietary HARP (Hillside Adjusted Risk Point) measure--just because the market is expensive doesn't mean there aren't some decent-looking bonds out there.  Contrasting this list with the ones from last week has some strategic implications you may want to consider.  Our head of equity research, Jeff Alton, takes a brief tour through a couple of names on the list.

In addition, our contributor Roman Terekhin examines a group of health-care convertible issuers that might be takeover candidates, and estimates how the convertibles might be affected.

We also provide a quick update regarding recent developments at EZCORP, whose new issue we profiled last month on our website.

Finally, we begin to introduce our team to you, beginning with yours truly today.

Click here to download the third issue of Hybrid Vigor (http://hillsi.de/HybridVigor0103)

Thanks again for your interest and support!

Bill Feingold
Co-Founder and Managing Principal
Hillside Advisors LLC

SMID Cap Healthcare Convertibles : Conference Insights

The principals of Hillside Advisors have long been fans of biotech convertibles—it’s a match almost as good as what Mr. Reese came up with mixing chocolate and peanut butter.  Unlike most industries, biotech recognizes its need for a constant flow of capital-market lifeblood and acts accordingly. Biotech companies don’t hesitate to float new shares after good news catapults the stock.

Read More